Elixir Medical Clinical Evaluation of the Novolimus-Eluting Coronary Stent System: A Randomized Study "EXCELLA II STUDY"

Inclusion Criteria: * The patient has a planned intervention of a single lesion in one or two separate major epicardial territories. Each lesion/vessel must meet the following criteria: * De novo * The target lesion reference site must be visually estimated to be \> 2.5 mm and \< 3.5 mm in diameter. * The target vessel must be a major coronary artery or major branch with a visually estimated stenosis of \> 50% and \<100%. * The visually estimated target lesion must be able to be covered by a single, 14, 18 or 28mm stent Elixir Stent or a single 14, 18, 24 or 30mm Endeavor Stent. Note that the 8mm Endeavor Stent will not be used in this study. * Maximum lesion length is 24 mm. * \> TIMI 1 coronary flow. Exclusion Criteria: * The patient has a known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, mTOR inhibitor class drugs, cobalt chromium alloy, methacrylate or polylactide polymer, or sensitivity to contrast which cannot be adequately premedicated. * There will be an untreated significant lesion of \> 40% diameter stenosis remaining proximal or distal to the target site after the planned intervention. * Total occlusion or TIMI 0 coronary flow in the target vessel. * Restenosis lesion * The proximal target vessel or target lesion is severely calcified by visual assessment. * Aorto-ostial location, unprotected left main lesion location, or a lesion within 5 mm of the origin of the LAD or LCX. * Lesion involvement of a significant side branc…